Company Filing History:
Years Active: 2019-2024
Title: Innovations by Harald Svensen in Eye Treatment
Introduction
Harald Svensen is an accomplished inventor based in Ålesund, Norway. He has made significant contributions to the field of ophthalmology, particularly in the treatment of eye disorders. With a total of two patents to his name, Svensen's work focuses on innovative compositions for treating dry eye disease and meibomianitis.
Latest Patents
Svensen's latest patents include a composition for the treatment of dry eye disease and meibomianitis. This application relates to compositions specifically designed for eye disorders, particularly dry eye disease (DED) and meibomianitis. The composition comprises very long chain polyunsaturated fatty acids derived from natural oils. Furthermore, the invention provides a method for treating DED and meibomianitis by administering a composition containing these fatty acids. The compositions are suitable for both oral and local applications. Another patent involves a method of producing a composition with a high concentration of very long chain polyunsaturated fatty acids (VLCPUFAs) from natural oils such as fish oil, squid oil, algal oil, and krill oil. This patent also discloses a process for isolating separate fractions of VLCPUFAs with identical chain lengths but different degrees of unsaturation.
Career Highlights
Svensen is currently associated with Epax Norway AS, a company known for its focus on high-quality omega-3 products. His work at Epax has allowed him to explore and develop innovative solutions for eye health, contributing to advancements in the treatment of common eye disorders.
Collaborations
Throughout his career, Svensen has collaborated with notable colleagues, including Harald Breivik and Iren Merete Skjåstad Stoknes. These collaborations have further enriched his research and development efforts in the field of ophthalmology.
Conclusion
Harald Svensen's contributions to the treatment of eye disorders through his innovative patents highlight his dedication to improving eye health. His work continues to pave the way for new therapeutic options in ophthalmology.